News Search Results
Jul 01, 2025, 07:00 ET Frontage Announces Expansion of Business in Canada with New Leadership
provider of comprehensive, high-quality R&D services, supporting Canada's vision to become a dynamic hub for biotechnology and pharmaceutical innovation." About Frontage (
More news about: Frontage Laboratories, Inc.
Jul 01, 2025, 06:30 ET Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform
Sana Biotechnology (NASDAQ: SANA),
More news about: Flagship Pioneering
Jul 01, 2025, 01:40 ET HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement
More news about: HanchorBio Inc.
Jun 30, 2025, 17:31 ET GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion | DelveInsight
highly targeted therapies. Pharmaceutical companies are increasingly investing in GPCR-focused pipelines, often in collaboration with biotechnology firms and academic research institutions. Strategic partnerships, licensing deals, and acquisitions are common, aiming to access novel chemistries
More news about: DelveInsight Business Research, LLP
Jun 30, 2025, 16:38 ET Announcement of fully underwritten rights issue
www.bergenbio.com About Oncoinvent ASA Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide
More news about: Oncoinvent AS
Jun 30, 2025, 16:36 ET Announcement of fully underwritten rights issue
www.bergenbio.com About Oncoinvent ASA Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide
More news about: Oncoinvent AS
Jun 30, 2025, 16:31 ET BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
field, improving the lives of patients with cancer in the peritoneal cavity." About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting
More news about: Oncoinvent AS
Jun 30, 2025, 16:28 ET BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
field, improving the lives of patients with cancer in the peritoneal cavity." About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting
More news about: Oncoinvent AS
Jun 30, 2025, 16:05 ET Halozyme Therapeutics Added to Russell 1000® Index
one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Jun 30, 2025, 16:02 ET Nektar Therapeutics Announces Proposed Public Offering
June 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten
More news about: Nektar Therapeutics
Jun 30, 2025, 15:00 ET Marine Collagen Market to Reach $2.32 Billion by 2032, Driven by Cosmetics Industry Demand and Health Awareness, Says Meticulous Research®
Titan Biotech Limited, ITALGEL S.p.A., Amicogen Co. Ltd., BHN Co. Ltd., ConnOils LLC, HUM Nutrition Inc., Vital Proteins LLC, Hangzhou Nutrition Biotechnology Co. Ltd., and ETChem, focusing on sustainable sourcing practices, product innovation, and expansion into emerging markets. Request a customized
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 14:25 ET Europe Single-use Bioreactors Market to Reach $3.34 Billion by 2032, Growing at a CAGR of 15.3% from 2025, Says Meticulous Research®
Europe single-use bioreactors market is driven by rapid adoption of disposable technology in pharmaceutical and biotechnology industries, growing demand for biopharmaceuticals, substantial government support for bioproduction and biopharma products, and significant capacity
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 14:14 ET North America LIMS Market to Reach $763.5 Million by 2032, Growing at a CAGR of 7.1% from 2025, Says Meticulous Research®
capabilities to meet the growing demand for efficient data management, regulatory compliance, and enhanced laboratory productivity across pharmaceutical, biotechnology, food & beverage, and environmental testing sectors. For more comprehensive insights, download the FREE report sample:
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 12:42 ET Rubin and Rudman Partner Susan Grandis Named a 2025 "Go To Family Law Lawyer" by Massachusetts Lawyers Weekly
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Jun 30, 2025, 12:29 ET Regenerative Medicine Market to Reach $45.66 Billion by 2032, Growing at a CAGR of 22.0% from 2025, Says Meticulous Research®
Strategic Market Opportunities and Innovation Drivers The market presents extraordinary growth opportunities through advanced biotechnology integration, personalized medicine development, and expansion of therapeutic applications across multiple disease areas. Companies are discovering
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 11:40 ET Leather for Automotive Seats Market Size Expected to Reach USD 69.12 Bn 2031, Growing at CAGR of 5.3%, Booming Automotive Industry Fuels Growth | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jun 30, 2025, 11:30 ET Metagenomics Market to Reach $7.78 Billion by 2032, Growing at a CAGR of 15.8% from 2025, Says Meticulous Research®
programs, and established biotechnology ecosystem facilitating rapid innovation and commercialization of metagenomic solutions. Asia-Pacific emerges as a high-growth region during the forecast period, propelled by expanding biotechnology sectors, increasing government
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 11:15 ET Protein Expression Market to Reach $5 Billion by 2032, Growing at a CAGR of 7.6% from 2025, Says Meticulous Research®
emerging opportunities in underpenetrated economies, and the critical need for advanced protein synthesis technologies across pharmaceutical research, biotechnology development, and industrial applications. The industry is experiencing transformational growth through advanced mammalian cell expression
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 11:01 ET Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market
Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced the successful closing of its $18 million
More news about: Gallant
Jun 30, 2025, 11:00 ET Whole Genome Sequencing Market to Reach $8.35 Billion by 2032, Growing at a CAGR of 15.4% from 2025, Says Meticulous Research®
Innovation The global whole genome sequencing market features an innovative competitive ecosystem comprising specialized genomics companies, biotechnology firms, pharmaceutical companies, and integrated healthcare technology providers. This diverse landscape fosters rapid technological advancement
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 10:45 ET Sterilization Equipment Market to Reach $29.2 Billion by 2032, Growing at a CAGR of 8.2% from 2025, Says Meticulous Research®
efficiency, precision, and environmental sustainability in sterilization processesPharmaceutical & Biotechnology Growth: Expanding demand from pharmaceutical and biotechnology industries for specialized sterilization solutions supporting complex biologics manufacturing and sterile processing
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 10:30 ET Neurogenomics Market to Reach $5.48 Billion by 2032, Growing at a CAGR of 17% from 2025, Says Meticulous Research®
disorders. This segment is also expected to register the highest CAGR during the forecast period. Based on end user, the Pharmaceutical & Biotechnology Companies segment leads the market with 44% share in 2025, reflecting high adoption of advanced technologies for research, high availability of
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 10:15 ET IVD Assay Development Market to Reach $9.15 Billion by 2032, Growing at a CAGR of 8.1% from 2025, Says Meticulous Research®
development market features a diverse competitive ecosystem comprising specialized contract development organizations, pharmaceutical companies, biotechnology firms, and integrated diagnostic solutions providers. This dynamic landscape fosters rapid technological advancement through sophisticated assay
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 10:06 ET AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
June 30, 2025 /PRNewswire/ -- AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies for hematologic cancers and autoimmune diseases, today announced it has been awarded a grant of
More news about: AvenCell Therapeutics, Inc.
Jun 30, 2025, 10:01 ET Autoimmune Disease Diagnostics Market to Reach $11.45 Billion by 2032, Growing at a CAGR of 7.5% from 2025, Says Meticulous Research®
Innovation The global autoimmune disease diagnostics market features an innovative competitive ecosystem comprising specialized diagnostic companies, biotechnology firms, and integrated healthcare technology providers. This diverse landscape fosters rapid technological advancement through sophisticated biosensor
More news about: Meticulous Market Research Pvt. Ltd.